Ligand Pharmaceuticals Inc.

470 articles with Ligand Pharmaceuticals Inc.

• Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment

  10/23/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury ® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand’s Captisol ® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 treatment in the Un

• HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery

  10/12/2020

  HITGEN announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. to acquire Vernalis Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research.

• Ligand to Divest Vernalis Research Operations

  10/12/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the terms of the agreement, Ligand will retain economic rights on complet

• Ligand to Host Virtual Investor Day on October 20th

  10/2/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20 th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt Foehr, President and Chief Operation Officer Matt Korenberg, Chief Financial Officer

• Ligand Completes Acquisition of Pfenex Inc.

  10/1/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved

• Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.

  9/30/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain specified milesto

• Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

  9/23/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the

• Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

  9/10/2020

  Ligand Expands OmniAb ® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery

• Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

  9/1/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference.

• Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

  8/31/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a cont

• Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

  8/25/2020

  Ligand OmniAb ® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis IMVT-1401 is a novel anti-FcRn OmniAb-derived antibody delivered by subcutaneous injection Registration-enabling Phase 3 trial expected to initiate in the first half of 2021 SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, I

• Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma

  8/24/2020

  Ligand Announces Amgen’s KYPROLIS ® Approved by FDA as Combination Regimen with DARZALEX ® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Capti

• 

  Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform

  8/11/2020

  Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.

• CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

  8/7/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based chemotherapy met its pre-specified primary endpoint, as assessed by the independent Data Monitoring Committee at the planned interim analysis of CS1001-302, a randomized, double-blind Phase 3 clinical trial for the first-line treatment of stage IV squamous

• Ligand Reports Second Quarter 2020 Financial Results

  8/3/2020

  Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates.

• Ligand’s Second Quarter Financial Results to be Reported August 3rd

  7/16/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020.

• Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

  6/15/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical company based in France, to jointly identify and enable new therapeutic targets. The new three-year research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as par

• Ligand CEO Issues Letter to Captisol Customers

  6/1/2020

  Ligand Pharmaceuticals Incorporated announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers.

• Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

  5/29/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new pro

• Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics

  5/28/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors.